Last $87.34 USD
Change Today +0.45 / 0.52%
Volume 548.0K
CVD On Other Exchanges
Symbol
Exchange
New York
Stuttgart
As of 8:04 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

covance inc (CVD) Snapshot

Open
$86.96
Previous Close
$86.89
Day High
$87.39
Day Low
$86.62
52 Week High
04/3/14 - $106.50
52 Week Low
07/29/13 - $79.11
Market Cap
5.0B
Average Volume 10 Days
323.1K
EPS TTM
$3.36
Shares Outstanding
57.4M
EX-Date
--
P/E TM
26.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for COVANCE INC (CVD)

covance inc (CVD) Related Bloomberg News

View More Bloomberg News

covance inc (CVD) Related Businessweek News

View More BusinessWeek News

covance inc (CVD) Details

Covance Inc. provides early-and late-stage services to the pharmaceutical, biotechnology, and medical device industries. Its early-stage development services include preclinical and clinical pharmacology services. The company’s late-stage services include biomarker services to biotech and pharmaceutical customers, with full management of Phase II and III clinical studies. It also provides lab testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is based in Princeton, N.J.

11,863 Employees
Last Reported Date: 02/27/14
Founded in 1987

covance inc (CVD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Corporate Senior ...
Total Annual Compensation: $407.5K
Executive Vice President and Group President ...
Total Annual Compensation: $455.5K
Executive Vice President and Group President ...
Total Annual Compensation: $421.0K
Chief Information Officer, Corporate Senior V...
Total Annual Compensation: $446.0K
Compensation as of Fiscal Year 2013.

covance inc (CVD) Key Developments

Covance Announces Management Appointments

Covance has appointed Robert Wasserman as vice president and global therapeutic area head of oncology and Rogelio Mosqueda-Garcia as global vice president of early clinical services within medical and scientific affairs. Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. Dr. Mosqueda-Garcia will provide scientific direction for the Clinical Pharmacology Services and Early Clinical Development groups. He also will work internally and externally to address issues of clinical pharmacology studies in patients, integration of biomarkers in early development, and the creation of novel approaches to establish proof of concept in development programs of new drug candidates. Dr. Mosqueda-Garcia previously served as Executive Director in Clinical Pharmacology at AstraZeneca Pharmaceuticals. He held senior roles in the Clinical Discovery Group at Bristol-Myers Squibb and in the Clinical Pharmacology Department at DuPont Pharmaceuticals.

Covance Inc. Introduces Covance MarketPlace

Covance Inc. has introduced Covance MarketPlace, a new solution that reportedly enables its biotechnology and pharmaceutical clients to find and forge new partnerships. Sourcing high-quality drug candidates efficiently and effectively is a pivotal step in the industry's quest to accelerate the development and launch of innovative new medicines. Covance MarketPlace helps biotechnology companies more effectively showcase their molecules to larger pharmaceutical companies as they continue to increase their own in-licensing efforts. With Covance conducting development work for all the molecules in Covance MarketPlace, prospective partners can be confident in the quality of the data, design of the plan and regulatory acceptance.

Covance Considers Acquisitions

Covance Inc. (NYSE:CVD) will consider acquisitions. Alison Cornell, Coorporate Senior Vice President and Chief Financial Officer of Covance said, "I would say we have kind of a three-pronged approach that we use in terms of use of cash. So first is invest in the business to drive growth, drive free cash flow. Second are acquisitions. So probably folks don't realize, but we look at acquisition candidates almost every day of the week, and we look for more tuck-in capability. We see to go outside of the US where demand is great; we will be doing acquisitions in the nutritional chemistry space.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVD:US $87.34 USD +0.45

CVD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $54.23 USD +0.38
GFK SE €34.66 EUR -0.22
ICON PLC $47.12 USD -0.37
IMS Health Holdings Inc $26.60 USD -0.31
PAREXEL International Corp $54.07 USD -0.20
View Industry Companies
 

Industry Analysis

CVD

Industry Average

Valuation CVD Industry Range
Price/Earnings 27.4x
Price/Sales 2.0x
Price/Book 3.0x
Price/Cash Flow 16.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVANCE INC, please visit www.covance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.